English
SpanishTrusted Resources: Evidence & Education
Scientific literature and patient education texts
Comparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Active Graves’ Ophthalmopathy: A Prospective, Randomized Controlled Trial
source: Endocrine Journal
year: 2017
authors: He Y, Mu K, Liu R, Zhang J, Xiang N
summary/abstract:The intravenous methylprednisolone (iv MP) strategy for Graves’ ophthalmopathy (GO) and evaluation of its activity against the disease warrants further exploration. A prospective randomized controlled trial for 3 months was performed in a tertiary referral teaching hospital to compare the efficacy and safety of two different regimens of iv MP, and determine the value of clinical activity score (CAS) and T2 relaxation time (T2RTs) and areas of extraocular muscles (EOMs) by magnetic resonance imaging for diagnosis of active GO.
Forty patients with moderate to severe GO and CAS >= 3 or 1 =< CAS < 3 with prolonged T2RTs on EOMs were randomly assigned to a monthly (MR: 1.5 g iv MP monthly for 3 months) or weekly (WR: 0.5 g iv MP weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks) regimen. Overall response based on ophthalmic symptoms, T2RTs, areas of EOMs and adverse effects were recorded at each visit. The total rate of response was 71.9%.
Rates of improved, unchanged, deteriorated were similar between the MR and WR groups (p>0.05). The maximum T2RTs and areas significantly decreased at the end of intervention in both groups (p<0.05). Results show that both MR and WR are effective and safe in treatment of GO. T2RTs combined with CAS can sensitively detect active GO and predict the response to iv MP.
organization: Huazhong University of Science & Technology, ChinaDOI: 10.1507/endocrj.EJ16-0083
read more
myBinderRelated Content
-
What Is Thyroid Eye Disease (TED)?https://www.youtube.com/watch?v=OVUZcQWF...
-
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
Mycophenolate Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or...Background: European guidelines recomme...
-
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
-
Early Diagnosis of Thyroid Eye Disease (TED)Early Symptoms TED can first present wi...
-
FDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye DiseaseThe Dermatologic and Ophthalmic Drugs Ad...
-
Risk Factors for Graves’ Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.Context: Previous association studies s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
